Informationen:
Fehler:
ID
14571
Beschreibung
Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant; ODM derived from: https://clinicaltrials.gov/show/NCT01083706
Link
https://clinicaltrials.gov/show/NCT01083706
Stichworte
Versionen (1)
- 21.04.16 21.04.16 -
Hochgeladen am
21. April 2016
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Eligibility Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities NCT01083706
Eligibility Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities NCT01083706
- StudyEvent: Eligibility
Ähnliche Modelle
Eligibility Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities NCT01083706
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
mds
Item
mds, cmml or aml patients (as diagnosed by world health organization [who] criteria) with evidence of relapse or progression at >= day 28 and < day 100 post-transplant
boolean
C3463824 (UMLS CUI [1])
cytogenetic abnormalities
Item
recurrent or increased cytogenetic abnormalities by standard karyotype or fluorescence in situ hybridization (fish) (the cytogenetic abnormalities must have been previously documented at some time point between diagnosis and date of stem cell transplant)
boolean
C0008625 (UMLS CUI [1])
Myeloblast
Item
morphologic evidence of recurrence or increased abnormal myeloblasts in peripheral blood or marrow
boolean
C0229633 (UMLS CUI [1])
Myeloblasts flow cytometric
Item
flow cytometric evidence of disease as determined by recurrent or increased abnormal myeloblasts in peripheral blood or marrow
boolean
C0580952 (UMLS CUI [1,1])
C0201644 (UMLS CUI [1,2])
C0201644 (UMLS CUI [1,2])
extramedullary relapse
Item
extramedullary relapse (local radiotherapy will be allowed)
boolean
C2854080 (UMLS CUI [1])
mds, cmml, or aml patients
Item
mds, cmml, or aml patients with persistent stable disease or persistent disease with regression at >= day 28 and < day 100 post-transplant; the inclusion of patients with persistent stable or persistent regressing disease in this protocol is not meant to advocate treatment; however, if the attending physician is inclined to offer treatment then these patients would be eligible for this study
boolean
C3463824 (UMLS CUI [1])
C0023480 (UMLS CUI [2])
C0023480 (UMLS CUI [2])
cytogenetic abnormalities
Item
persistence of cytogenetic abnormalities by standard karyotype or fish
boolean
C0008625 (UMLS CUI [1])
abnormal myeloblasts
Item
persistent morphologic evidence of abnormal myeloblasts (in patients with cmml the monoblastoid population is included) in peripheral blood or marrow
boolean
C0205161 (UMLS CUI [1,1])
C0229633 (UMLS CUI [1,2])
C0229633 (UMLS CUI [1,2])
Extramedullary
Item
extramedullary persistence or regression
boolean
C1517060 (UMLS CUI [1])
Refractory Disease
Item
refractory disease at time of stem cell transplant; patients who received chemotherapy prior to transplant with no evidence of response by international working group (iwg) criteria
boolean
C1514815 (UMLS CUI [1])
Bone marrow myeloblasts
Item
>= 10% bone marrow myeloblasts as measured by morphology
boolean
C1993094 (UMLS CUI [1])
central nervous system
Item
evidence of central nervous system (cns) disease at time of relapse by morphology or flow (a diagnostic lumbar puncture [lp] is not required at time of relapse)
boolean
C0007684 (UMLS CUI [1])
serum creatinine
Item
serum creatinine > 2 x uln (upper limit of normal)
boolean
C0201976 (UMLS CUI [1])
aspartate aminotransferase
Item
aspartate aminotransferase (ast)/ alanine aminotransferase (alt) > 2x uln
boolean
C0201899 (UMLS CUI [1])
eastern cooperative oncology group
Item
performance status > 2 (eastern cooperative oncology group [ecog] scale)
boolean
C1512162 (UMLS CUI [1])
Protocol Compliance
Item
patients with severe disease other than mds, cmml or aml which would be expected to prevent compliance with treatment
boolean
C0525058 (UMLS CUI [1])
C0009488 (UMLS CUI [2])
C0009488 (UMLS CUI [2])
severe infections
Item
patients with severe infections (pneumonia, sepsis, etc) within the 2 weeks prior to the anticipated start of protocol treatment
boolean
C3714514 (UMLS CUI [1])
Keine Kommentare